Oncology & Hematology Coding Alert

Correction:

Restrict V58.61 to Secondary Spot

For your PT test monitoring encounters, be sure to limit V58.61 to the secondary diagnosis role. In Oncology and Hematology Coding Alert, Vol. 11, No. 10, the second section of "Conquer In-Office Coumadin Coding, Easy as 1-2-3" incorrectly indicated that V58.61 should be a primary diagnosis. The section should read as follows: "Do this: If the reason for the PT test is to monitor the anticoagulation medication's effectiveness, look to V58.83 (Encounter for therapeutic drug monitoring) as your primary diagnosis. ICD-9 instructs you to 'Use additional code for any associated long-term (current) drug use,' and in the case of Coumadin, you should report V58.61 (Long-term [current] use of anticoagulants)."
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in Revenue Cycle Insider
  • 6 annual AAPC-approved CEUs
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more

Other Articles in this issue of

Oncology & Hematology Coding Alert

View All

Which Codify by AAPC tool is right for you?

Call 844-334-2816 to speak with a Codify by AAPC specialist now.